Cambium Bio LtdASX: CMB

Corporate Presentation - September 2026

Sep 29, 2026 at 7:18 PM EDT · Issued by Cambium Bio Ltd via ASX

Filed with ASX · Sep 29, 2026 at 7:18 PM EDT · 29 pages · English and French

On 6ix: 6ix.com/news/corporate-presentation-september-2026-2

Release

Unit 2.06/31 Lexington Drive, Bella Vista, NSW 2153 Ph: 1300 995 098 • www.cambium.bio • ABN 13 127 035 358 ASX Announcement 30 September 2026 Cambium CEO, Karolis Rosickas presentation at ShareCafe and Finance News Network (FNN) Sydney, Australia, 30 September 2026: Cambium Bio Limited...

Cambium Bio Ltd on 6ix

In the deck

Cambium Bio — Investor Presentation (September 2026)29 slidesSep 30, 2026

Earlier from Cambium Bio

Date of AGM and Closing Date for Director NominationsSep 27
Notification of cessation of securities - CMBSep 23
Notification regarding unquoted securities - CMBSep 22
Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye DiseaseSep 16
Cambium Bio Secures A$10.85 Million Funding PackageSep 15

Later from Cambium Bio

Proposed issue of securities - CMBOct 7
Notice of Annual General Meeting and Proxy formOct 7
Access Letter and Online Meeting GuideOct 7
Quarterly Activities/Appendix 4C Cash Flow ReportOct 28

All Cambium Bio news releases

Follow Cambium Bio into a list and get an email when it puts out news.

Follow Cambium Bio